Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01701323 · ClinicalTrials.gov registry record · Phase 1
Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Nohla Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01701323: Clinical Trial Phase 1 study, sponsored by Nohla Therapeutics.
NCT01701323 is a Phase 1 study that was terminated before completion, run by Nohla Therapeutics. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01701323, a Phase 1 study, was terminated before completion, sponsored by Nohla Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This pilot clinical trial studies infusion of expanded cord blood hematopoietic progenitor cells following combination chemotherapy in treating younger patients with acute myeloid leukemia that has relapsed or has not responded to treatment. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy also kills healthy infection-fighting cells, increasing the risk of infection. The infusion of expanded cord blood hematopoietic progenitor cells may be able to replace blood-forming cells that were destroyed by chemotherapy. This cellular therapy may decrease the risk of infection following chemotherapy.
Interventions
- DRUG Cytarabine
- DRUG Fludarabine Phosphate
- DRUG Filgrastim
- BIOLOGICAL Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-12-10 |
| Est. Completion | 2018-05-10 |
| Phase | Phase 1 |
Why NCT01701323 stopped before completion
NCT01701323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 4 interventions - of which Cytarabine is the first listed.
NCT01701323 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01701323 about?
NCT01701323 is a clinical study titled "Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia". This pilot clinical trial studies infusion of expanded cord blood hematopoietic progenitor cells following combination chemotherapy in treating younger patients with acute myeloid leukemia that has relapsed or has not responded to treatment. Chemotherapy drugs work in different ways to stop the grow...
What is the current status of trial NCT01701323?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2012-12-10. Estimated completion is 2018-05-10.
What interventions are being tested in trial NCT01701323?
The interventions under investigation include: Cytarabine (DRUG), Fludarabine Phosphate (DRUG), Filgrastim (DRUG), Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT01701323?
This trial is sponsored by Nohla Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01701323's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI